Ampio Presents at Roth Capital Partners 2020 MedTech Innovation Forum Focusing on COVID-19 Clinical Trial Activities
Ampio Presents at Roth Capital Partners 2020 MedTech Innovation Forum Focusing on COVID-19 Clinical Trial Activities |
[26-October-2020] |
ENGLEWOOD, Colo., Oct. 26, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the Company will present at the 2020 MedTech Innovation Forum hosted by Roth Capital Partners on Wednesday, October 28, 2020. The Company's presentation will (i) review preliminary results from the randomized, controlled study of intravenous Ampionâ„¢ for treatment of hospitalized COVID-19 infected adult patients requiring supplemental oxygen and (ii) further discuss its future COVID-19 plans. Ampion addition to standard of care ("SOC") was compared to patients treated with the SOC including anti-viral therapy ("remdesivir"). Safety was determined by presence of adverse events during the trial and indications of efficacy was determined by the Ordinal Scale, a measure developed by the WHO (a range of 0-8, with 0 defined as uninfected with no clinical or virological signs of infection and 8 denoting death) and calculated as a change from admission to discharge or at the time of discharge from the hospital. The primary end-point was safety and, as previously reported, there were no drug related adverse events for a period of 5 days subsequent to the treatment with Ampion. The secondary end point was improvement in the score as measured by the Ordinal Scale. Ampion addition to the SOC compared to the SOC alone or SOC plus remdesivir, demonstrated that the addition of Ampion to the SOC resulted in better average outcomes (reduction in 3 points for Ampion+ SOC versus 1.5 and 2.25 points for SOC and SOC+remdesivir, respectively). Average scores as measured by the Ordinal Scale at the time of discharge from the hospital were also better for Ampion+SOC compared to the other groups (a score of 1 for Ampion +SOC versus 2.75 and 1.75 for SOC and SOC+remdesivir, respectively). About Ampio Pharmaceutical Forward Looking Statements Company Contact View original content to download multimedia:http://www.prnewswire.com/news-releases/ampio-presents-at-roth-capital-partners-2020-medtech-innovation-forum-focusing-on-covid-19-clinical-trial-activities-301159523.html SOURCE Ampio Pharmaceuticals, Inc. | ||
Company Codes: AMEX:AMPE |
© 2020 PR Newswire. All Rights Reserved.